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Topical microbicides are intended for frequent use by women in reproductive age. Hence, it is essential to evaluate their impact
on mucosal immune function in the vagina. In the present study, we evaluated nisin, a naturally occurring antimicrobial peptide
(AMP), for its eﬃcacy as an intravaginal microbicide. Its eﬀect on the vaginal immune function was determined by localizing Toll-
like receptors (TLRs-3, 9) and cytokines (IL-4, 6 , 10 and TNF-α) in the rabbit cervicovaginal epithelium following intravaginal
administration of high dose of nisin gel for 14 consecutive days. The results revealed no alteration in the expression of TLRs and
cytokines at both protein and mRNA levels. However, in SDS gel-treated group, the levels were signiﬁcantly upregulated with
the induction of NF-κB signalling cascade. Thus, TLRs and cytokines appear as sensitive indicators for screening immunotoxic
potential of candidate microbicides.
Copyright © 2008 Sadhana M. Gupta et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Topical microbicides are being sought for preventing the
transmission of human immunodeﬁciency virus (HIV)
infection and other sexually transmitted infections (STIs)
[1]. The success of anti-HIV/STI microbicides depends on
their ability to maintain natural vaginal defenses, since
the stratiﬁed epithelium of human vagina in unison with
the microﬂora provides an eﬃcient barrier against HIV-
1[ 2]. It is known that inﬂammatory conditions induced
by pathogens or chemical irritants may lead to a higher
risk of acquiring and transmitting HIV-1 due to epithelial
disruption and recruitment of HIV-1 by immune cells [3].
During early eﬀorts to develop safe and eﬀective topical
microbicides to eliminate the risk of sexual transmission of
STIs/HIV-1, Nonoxynol-9 (N-9), a chemical-based product,
emerged as the lead candidate due to its potent activity
against microbes in vitro and widespread commercial use
as a contraceptive [4, 5]. However, clinical trials revealed
that frequent use of N-9 resulted in inﬂammatory lesions
and ulceration of the genital tract mucosa creating a direct
portalofentryforHIV-1[6,7].Twootherproducts,cellulose
sulfate (6%) and carraguard also failed as microbicides
despite preclinical safety trials (http://www.aidsmap.com).
One of the most promising alternatives to chemical-
/detergent-based vaginal microbicides appears to be the
naturally occurring antimicrobial peptides (AMPs) [8, 9].
They represent ancient host defense eﬀector molecules
produced by the innate immune system in response to
pathogenic microbes or inﬂammatory stimuli. The most
extensively characterized AMP is the lantibiotic nisin, a 34
amino acid cationic, amphiphilic peptide having a molecular
mass of 3.5kDa [10, 11]. Our earlier studies have shown
that intravaginal administration of nisin does not trigger any
inﬂammatory response in CVE of rabbits [8, 12].
In the context of developing a safe microbicide, it
is also essential to determine its interference with the
vaginal mucosal immune function. A remarkable feature
of the immune cells of the vaginal mucosa is their ability
to recognize and discriminate invading microbes from
commensal bacteria or inﬂammatory agents [13, 14]. The
vaginal mucosal immune cells are equipped with diﬀerent2 Mediators of Inﬂammation
Toll-like receptors (TLRs), which belong to a large family
of highly conserved proteins that are essential pathogen-
speciﬁc recognition sensors of the innate immune system
[15–18] .S of a r ,1 1m e m b e r so ft h i sf a m i l yh a v eb e e n
identiﬁed on various cells [19–21]. TLR signalling is a key
component of communication between vaginal epithelial
cells and underlying immune cells in the lamina propria
[20, 22, 23]. Therefore, we presumed that TLRs may act
as suitable biomarkers for assessing vaginal inﬂammation
induced by candidate microbicides.
A critical gap in microbicide development has been
caused due to the absence of surrogate safety markers.
Since vaginal microbicides would be used repeatedly over
decades,itwouldbeadvantageoustoevaluatetheireﬀectson
vaginal innate immune defense system. Suitable biomarkers
are required to determine the changes that take place
in the mucosal environment at molecular level, including
induction of inﬂammation or loss of host vaginal defenses,
which are not reﬂected by histology [23]. A noninvasive
method to detect subtle tissue inﬂammation would be a
helpful adjunct to the histological ﬁndings. Considering the
pivotal role of TLRs and cytokines in vaginal mucosal innate
immunity, we carried out a study to determine the vaginal
immune response after intravaginal application of nisin gel.
For this study, we selected TLRs-3 and 9, and cytokines
(IL-4, 6, 10, and TNF-α) as they play an indispensable
role in host vaginal innate and adaptive immunity. TLRs-3
and 9 are known to be expressed on plasma membrane as
well as within the endosomes and stimulate memory B-cell
development, proliferation, and diﬀerentiation. They also
induce the secretion of anti-inﬂammatory cytokines from
mucosal epithelium when they sense inﬂammatory stimuli
[19]. The objectives of the present study were to (1) examine
the eﬀect of repetitive application of high dose of nisin
gel on vaginal mucosal immunity using rabbit model; (2)
investigate changes induced by nisin gel in the TLR and
cytokine milieu of rabbit vagina; and (3) determine the role
of TLRs and their downstream signalling cascade in host
vaginal defense mechanism. To the best of our knowledge,
this is the ﬁrst report to demonstrate the in vivo distribution
of TLRs and identify putative pathways driven by TLR
cytokine interactions in the CVE of rabbit after intravaginal
administration of microbicide, nisin gel.
2. MATERIALS AND METHODS
Nisin (Sigma Aldrich, St. Louis, USA, Lot # 075K1355)
was puriﬁed by gel ﬁltration chromatography on Sephadex
G-25 and RP-HPLC as described [24]. Brieﬂy, after initial
puriﬁcation by gel ﬁltration chromatography, the lyophilized
sample was acidiﬁed with 0.1% triﬂuoroacetic acid (Merck
Ltd, Mumbai, India) and applied onto a preparative C8
column (Vydac, Ill, USA) connected to a Dionex HPLC unit.
Peptide fractions were eluted in a three-step gradient of
0.01% triﬂuoroacetic acid in water and 0.01% triﬂuoroacetic
acid in 50% acetonitrile (Spectrochem, Mumbai, India): 0–
100% (60 minutes), held at 100% for 5 minutes and brought
back to 0% (100-0%). The individual peptide peaks were
collected and their absorbance was monitored at 220nm
using spectrophotometer (Shimadzu, UV-160, and Japan).
The positive fractions were pooled and concentrated by
lyophilization. Nisin gel (15.15mM equivalent to 50mg) was
formulated using 1% polycarbophil as a gelling agent, SDS
gel (56μMe q u i v a l e n tt o3 2 μg) in 1% polycarbophil, and
placebo gel using 1% polycarbophil.
2.1. Animals
Sexually mature female Belgium White Rabbits (mean age
7 ±1months;meanbodyweight,2.70 ±0.40kg)weremain-
tained under standard laboratory conditions (temperature
20 ± 1◦C, relative humidity 50 ± 10%, and 12 hours light:12
hours darkness cycle). Animals were housed individually in
stainless steel cages; food and water were made available ad
libitum. The study was approved by the Ethics Committee
of National Institute for Research in Reproductive Health
(NIRRH), Parel, and Mumbai. All measures taken were in
accordance with approved guidelines of Committee for the
purpose of Control and Supervision of Experiments on
Animals (CPCSEA), established by Government of India on
animal care.
2.2. Intravaginaladministrationofnisingelinrabbits
Rabbits were divided into three groups each consisting
of six animals. First group of animals received nisin gel
formulation prepared in 1% polycarbophil (15.15mM in
2 m Lo f1 %p o l y c a r b o p h i l / d a yf o r1 4c o n s e c u t i v ed a y s ) .
The second and third groups of rabbits received SDS gel
(56μM in 2mL of 1% polycarbophil/day/14 consecutive
days) and 2ml of 1% polycarbophil gel, respectively. The
gel formulations were delivered into the vagina using a 12-
cm ﬂexible catheter, inserted up to its 8cm mark. The body
weights of rabbits and clinical observations were recorded
daily, including swollen vulva areas, blood stained urine, and
soft stools.
On day 15, the cervicovaginal lavages (CVLs) were
collected from placebo and treated rabbits by administering
500μl of saline and animals were autopsied using CO2
asphyxiation. Samples were centrifuged at 1000g for 5
minutestoseparatesupernatantfromcelldebris.Thevaginal
tissues were slit open ventrally between the urethral oriﬁce
and fornix. Portions of cervicovaginal tissues were ﬁxed in
Bouin’s solution. Paraﬃns e ct i o n so f5μm thick were cut and
utilized for immunolocalization of TLRs (TLR-3 and 9) and
cytokines (IL-4, 6, 10, and TNF-α). The remaining tissues
were processed immediately for ﬂow cytometric evaluation
of TLRs and RT-PCR analysis.
2.3. IsolationofrabbitCVEcells
CVE tissue was isolated from three groups of rabbits, cut
into small fragments, and pooled (200–300 mg) groupwise
prior to being snap frozen on dry ice and stored in liquid
nitrogen until further analysis. On the day of analysis,
cell suspensions were prepared by enzymatic digestion
as described previously [25]. Brieﬂy, fragments of CVE
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St. Louis, USA) in 2.5% (w/v) pancreatin solution (Sigma)
for 1 hour at 4◦C, followed by 1 hour digestion at 22◦C
with constant rotation (120rpm). Digested tissues were
vortexed to release the epithelial sheets before passing cell
suspension through a 20μm nylon mesh (Millipore Corp.,
Billerica, MA, USA). Cells were aspirated through 20 gauge
needles to prepare isolated cells before resuspension in com-
plete Rosewell Park Memorial Institute-1640 (RPMI-1640)
medium (Life Technologies, Inc., Md, USA) (25mM HEPES
supplemented with 10% fetal bovine serum (Hyclone),
50μM 2-mercaptoethanol, 2mM L-glutamine, 100μg/mL
streptomycin, and 100U/mL penicillin) and then seeded
onto Nunc cell culture inserts (diameter, 10mm, pore size,
0.4μm) coated with diluted Matrigel (Sigma) at 300μl/apical
chamber of the cell culture insert. Inserts were placed into 24
well tissue culture plates containing 500μl of culture media
per well. The purity of epithelial cell cultures was evaluated
by using anti-CD45 antibody which showed that CVE cells
accounted for more than 90% of the cells present on each
insert.
2.4. Immunoﬂuourescent(IF)localizationofTLRs
The purpose of this experiment was to determine the
pattern of changes in TLR expression in CVE of placebo,
nisin, and SDS gel-treated rabbits. CVE tissue sections were
deparaﬁnized in xylene, rehydrated in descending grades of
alcohol, and ﬁnally washed in PBS (0.1M PBS, pH 7.4).
The nonspeciﬁc binding was blocked with 1:100 dilution of
normal goat serum and incubated at 37◦Cf o r1h o u r .A f t e r
washing in PBS, slides were incubated overnight at 4◦Cw i t h
1:100dilutionofgoatantihumanTLR-3andTLR-9antibody
(Imgenex) (cat # SC-8691 for TLR-3 and cat # IMG 305
for TLR-9) in PBS. The sections were washed in PBS, and
incubated with FITC conjugated donkey antigoat secondary
antibody (Sigma Aldrich, St. Louis, USA) at a dilution of
1:1000 at 37◦C for 1 hour in dark. Immunoﬂuorescence sig-
nals were captured using laser scanning confocal microscopy
(LSCM) (Zeiss, 510 meta, Germany).
2.5. Flowcytometricanalysis
Flow cytometry was performed on a FACS vantage ﬂow
cytometer (Becton Dickinson, USA) to evaluate the surface
expression of TLR-3 and 9 in CVE cells. Based on initial
optimization studies, the cells (1 × 106 /mL) were washed
brieﬂy in PBS, and nonspeciﬁc binding was blocked with
1:100 dilution of normal goat serum at 37◦Cf o r1h o u r .
For intracellular staining, cells were ﬁrst treated with ﬁxation
buﬀer (4% pararformaldehyde) followed by permeabiliza-
tion buﬀer (0.1% Triton X 100). After washing with PBS,
slides were incubated overnight at 4◦C with 1:100 dilution
of goat antihuman antibody to TLR-3 and TLR-9 in 1%
BSA in PBS. After washing in PBS, the cells were incubated
at 37◦C for 1 hour in dark with FITC conjugated donkey
antigoat secondary antibody at a dilution of 1:1000. After
washing ﬁve times in PBS, ﬂuorescence signals for each cell
weredetectedthrougha520nmargon-ionlaser.Weincluded
normal goat serum as appropriate –ve control to rule out
any nonspeciﬁc binding of antibody through Fc-receptors.
Data for a minimum of 10000 events was collected for
each sample. Fluorescence histograms and dot plots were
generated after gating the cell population using cell quest
software (http://facs.scripps.edu/).
2.6. Immunohistochemicallocalizationofcytokines
The immunohistochemical localization of proinﬂammatory
cytokines (IL-6 and TNF-α)w a sc a r r i e do u ta sp e rt h ek i t
protocol described by manufacturer (R&D systems, Minn,
USA) (cat # DTA00C for IL-6 and cat # DY206 for TNF-α).
The localization of IL-4 and 10 was performed using goat
antihuman primary antibody (Sigma Aldrich, cat # I7526 for
IL-4, I5020 for IL-10). Brieﬂy, cervicovaginal tissue sections
from placebo, nisin, and SDS gel-treated rabbits were
processed as described above. The endogenous peroxidase
activity was quenched by treating cervicovaginal tissues with
0.03% H2O2 in methanol for 10 minutes and rinsed in PBS
for 5 minutes. To rule out nonspeciﬁc binding, sections were
incubated in normal goat serum instead of primary antibody
and considered as negative controls. After washing with PBS,
slides were incubated with respective primary antibodies
overnight at 4◦C. Next day, slides were washed twice in
PBS and incubated for 1 hour at RT with 1:100 dilution
of donkey antigoat secondary antibody conjugated to horse
radish peroxidase (HRP) (Sigma Aldrich, cat # G6638).
After washing in PBS, the sections were incubated for
1 0m i n u t e sw i t h3 - 3  diaminobenzidine tetrahydrochloride
(DAB) (Sigma Aldrich, St. Louis, USA) containing Ni
2+ and
H2O2 in PBS. The tissue sections were then brieﬂy rinsed in
water, counterstained with hematoxylin. After dehydration
in alcohol series, sections were cleared in xylene, mounted
with DPX, and visualized using Olympus BX50 microscope.
2.7. Imageanalysis
Semiquantitative analysis of the immunoprecipitates of
cytokines was performed using image analysis software Bio-
vis 1.42 as detailed previously [26]. Brieﬂy, four areas from
each section were randomly selected for each animal in the
three groups. Images from these areas were grabbed by the
CCD camera. The integrated optical density (IOD) of each
area was calculated for the brown color immunoprecipitates.
Negative control slides were analyzed in a similar fashion.
The mean ± SDs were calculated for each group.
2.8. Measurementofcytokinelevelsin
cervicovaginallavages
Levels of proinﬂammatory (IL-6 and TNF-α), Th-2 type IL-
4, and anti-inﬂammatory cytokine (IL-10) in CVLs were
measured by ELISA as per the protocol discussed above.
Optical densities of the product formed were measured
by using ELISA reader (ELX 800, Bio-TEK Instruments).
Cytokine levels were calculated by quadratic regression anal-
ysis based on logarithmically transformed optical densities.
Interference of gel formulations in cytokine ELISA was ruled
out by spiking known concentrations of standards. Control4 Mediators of Inﬂammation
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Figure 1: Laser Scanning Confocal Microscope (LCMS) images
of TLR-9 protein expression in rabbit CVE after intravaginal
administrationofnisin(15.15mMin2mLof1%polycarbophilgel)
(b), SDS (56μM in 2mL of 1% polycarbophil gel), (c) and 2mL of
1% placebo gel (a) for 14 consecutive days. Expression was found
to be localized in the cytoplasm of cells. Note signiﬁcant increase
of TLR expression in SDS gel group (c) compared to placebo (a)
and nisin gel administered (b) groups. Similar expression pattern
was observed in TLR-5. The ﬁgures shown are the representative
pictures from three independent experiments (Mag X 40; inset
image X 630).
and treated samples were assayed in duplicate wells and the
experiment was repeated thrice.
2.9. MeasurementofPhospho-NF-kBp65inCVEcells
The activation of NF-kB signalling cascade in CVE tissue
was determined as per the manufacturer’s protocol using
Phospho-NF-kB p65 (Ser536) Sandwich ELISA kit (Cell
Signaling, MA, USA). Brieﬂy, cell lysates were prepared with
lysis buﬀer (20mM tris,150mM NaCl, 1mM EDTA,1mM
ethylene glycol-bis(2-aminoethyl)-N,N,N
 ,N
  (EGTA), 1%
Triton X-100, 2.5mM sodium pyrophosphate, 1mM β-
glycerophosphate, 1mM Na3 Vo4, 1μg/mL leupeptin) and
sonicated on ice. The lysates were centrifuged at 14000rpm
(Eppendorf 541R) for 10 minutes at 4◦C to pellet the
cell debris. The supernatants were collected, aliquoted, and
storedat −80◦Cinsingleusealiquots.Celllysateswereadded
to microwells coated with Phospho-NF-kB p65 (Ser536)
(93H1) mouse mAb and incubated overnight at 4◦C.
Following extensive washing with wash buﬀer, 100μlo f
Phospho-NF-kB p65 rabbit mAb (Cell Signaling, MA, USA,
cat # 3033) was added to the wells and incubated for 1 hour
at 37◦C to detect the captured Phospho-NF-kB p65 protein.
Afterwashing,100μlantirabbitIgGsecondaryantibodycou-
pledtoHRP(CellSignaling,MA,USA,cat#7074)wasadded
andincubatedat37◦Cfor1hourtorecognizetheboundanti-
body. 100μlo fs u b s t r a t e ,3  -3 tetramethylbenzidine (TMB)
was added and incubated for 10 minutes at 37◦Ct od e v e l o p
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Figure 2:FlowcytometricanalysisofTLRexpressioninrabbitCVE
cells after intravaginal administration of placebo, nisin (15.15mM
in 2mL of 1% polycarbophil gel) SDS (56μMi n2 m Lo f1 %
polycarbophil gel) and 2 mL of 1% polycarbophil gel. Mean
ﬂuorescence intensity for TLR-3 and 9 were signiﬁcantly increased
inSDSgel-treatedanimalscomparedtotheirrespectiveplaceboand
nisin gel-treated groups. The mean and error bars indicate standard
deviation of triplicate measurements obtained from three separate
experiments.
Placebo SDS gel Nisin gel
TLR-3
TLR-9
GAPDH
305bp
207bp
199bp
Figure 3: RT-PCR analysis of TLR- 3 and 9 expression. Total RNA
was extracted from CVE cells and subjected to RT-PCR analysis as
described in the Material and Methods. No change in TLR gene
expression was observed in nisin administered animals compared
to placebo gel-treated group. However, in SDS gel administered
animals, the expression of TLR genes was upregulated. House
keeping gene, GAPDH expression conﬁrms roughly equivalent
loading of RNA samples.
blue color. Reaction was stopped by adding 100μlo fs t o p
solution. The OD of yellow-colored product was measured
at 450nm by ELISA reader. Each value is the mean ± SD of
six individual observations obtained from three experiments
performed on diﬀerent days.
2.10. RNAisolationandRT-PCRanalysisofTLRs,
cytokines,anddefensin-1molecules
Total RNA was isolated from CVE tissue from nisin, SDS,
andplacebogel-treatedrabbitsbysequentialextractionusing
TriPure reagent according to the manufacturer’s protocol
(Roche, Germany). RNA was quantitated spectrophotomet-
rically at 260 and 280nm (UV-160A, Shimadzu, Japan).
The quality and integrity of RNA was determined by 1.5%Sadhana M. Gupta et al. 5
Table 1: Oligonucleotide primers used for the study.
Gene Accession No Primer sequence (5  →3 ) Product size (bp) Annealing temperature
IL-4 DQ 852343 F-AGTTCTACCTCCACCACAAGGT 212 60◦C
R-TCAGCTCTGACGCTTTGAGTAT
IL-6 NM 001082064 F-AGGAGCTGAGGAAAGAGATGTG 225 58◦C
R-TGTTTTCTTCGTCACTCCTGAA
IL-10 NM 001082045 F-TTCTTTCAATCGAAGGATCAGC 267 59◦C
R-CTCATTCATGGCTTTGTAGACG
TNF-α ID AB128153 F-CTAGCCCACGTAGTAGCAAACC 159 60◦C
R-GCTGAAGAGAACCTGGGAGTAG
TLR-3 NM 003265 F-GAT CTG TCT CAT AAT GGC TTG 305 60◦C
R-GAC AGA TTC CGA ATG CTT GTG
TLR-9 NM 017442 F-TTC CCT GTA GCT GCT GTC C 207 59◦C
R-ACA GCC AGT TGC AGT TCA CC
Defensin-1 NM 001082299 F-CTCTGCTTGCTGCCATTCTC 196 60◦C
R-AATCGTCTGCAAGTACAGGACAC
GAPDH NM 01082253 F-CCATTCATTGACCTCCACTACA 199 59◦C
R-CGTTGCTGACAATCTTGAGAGA
denaturing formaldehyde agarose gel electrophoresis and
used for semiquantitative RT-PCR. Prior to ampliﬁcation,
all RNA samples were treated with RNase-free DNase-I
(Qiagen) to preclude genomic DNA contamination. Brieﬂy,
the reaction was carried out in a PTC-200 thermal cycler
(MJ Research, Maryland, USA) in a total volume of 50μl
reaction mixture containing 10μl5 XR T - P C Rb u ﬀer, 2μl
dNTP mixture, 1μle n z y m em i x ,2μlo f0 . 4μMe a c hp r i m e r ,
1μlt o t a lR N A( 2μg), 1μlD T Ts o l u t i o n ,a n d3 1μlR N A s e
free water. RT PCR to synthesize cDNA was carried out at
50◦C for 30 minutes followed by ampliﬁcation using gene-
speciﬁc primers (Table 1) for 30–40 cycles at 94◦Cf o r3 0
seconds, annealing at 55–64◦C for 30 seconds, extension at
68◦C for 40 seconds followed by a ﬁnal extension at 68◦Cf o r
7 minutes. Reaction was ampliﬁed in the absence of reverse
transcriptase as negative control. A nontemplate control
reactionwasalsoincludedtoensurelackofDNAcontamina-
tion. Housekeeping gene, GAPDH served as internal loading
control. PCR products were electrophoresed through 1.5%
agarose gel, stained with EtBr (0.5μg/mL) (Sigma Aldrich,
St. Louis, USA), visualized by UV transillumination, and
imaged using Gel Doc system (Bio-Rad, Calif, USA).
2.11. Statisticalanalysis
In most instances, the results were expressed as mean
± standard deviations. Statistically, signiﬁcant diﬀerences
between placebo and treatment groups were assessed using
analysis of variance or t test, and diﬀerences were considered
signiﬁcant if p values were <. 05.
3. RESULTS
3.1. ImmunoﬂuorescentlocalizationofTLRs
To determine the eﬀect of nisin gel on mucosal immunity,
rabbits were intravaginally administered with placebo, nisin,
and SDS gels. Representative images of TLR-9 immunoﬂu-
orescent localization of TLR-9 in CVE cells are shown in
Figure 1. TLR-9 was localized on the cell membrane and
also within the cytoplasm of CVE cells. Similar pattern of
expression was seen for TLR-3 (data not shown). Vaginal
delivery of high-dose nisin gel had no adverse eﬀect on the
expression of TLRs-3 and 9 compared to the placebo gel-
treated group.
3.2. FlowcytometryofTLRs
Theinﬂammatorypotentialofnisingelwasfurtherevaluated
byﬂowcytometry.Theresultsindicatednosigniﬁcantdiﬀer-
ence in the number of cells positive for TLR-3 and 9 between
placebo and nisin gel-treated groups (Figure 2). However,
in the SDS gel-treated group, mean ﬂuorescence intensity
for TLR-3 and 9 increased signiﬁcantly. The experiment
was repeated twice in duplicates and similar results were
obtained.
3.3. RT-PCRanalysisofTLRexpression
To determine whether vaginal administration of nisin gel
leads to modulation of TLRs and cytokine genes, expression
of TLR and cytokine mRNA transcripts were analyzed using
RT-PCR. As shown in Figures 3 and 9, RT-PCR results
demonstrated no change in the expression in nisin gel-
administered rabbits compared to the placebo group.
3.4. Immunohistochemicallocalizationofcytokines
Having demonstrated that CVE cells express TLRs-3 and 9,
we next investigated the modulation of various cytokines
in cervicovaginal tissue in response to microbicide gels by
immunohistochemistry. The expression of cytokines (IL-4,
6, 10, and TNF-α) was observed in the cytoplasm as secreted6 Mediators of Inﬂammation
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Figure 4: Immunohistochemical localization of IL-4 in the CVE
after intravaginal application of nisin (15.15mM in 2mL of 1%
polycarbophil gel) (b), SDS (56μM in 2mL of 1% polycarbophil
gel) (c) and 2mL of 1% polycarbophil gel (a) for 14 consecutive
days. To rule out the nonspeciﬁc binding, sections were incubated
in preimmune sera instead of primary antibody and considered as
negative control (d). Semi-quantitative comparison by measuring
integrated optical density (IOD) of immunoreactive IL-4 in treated
and placebo is shown (e). The IOD in each area was calculated for
the brown color immunoprecipitates. Each IOD value measured is
themean±SDofsixobservationsobtainedfromthreeindependent
samples. (Mag X 20) (EC = epithelial cells, SE = Squamous
epithelium, LP = lamina propria), (∗ = value is statistically
signiﬁcant at P<. 05).
products with no change in staining intensity between
placebo and nisin-treated groups. However, the levels were
signiﬁcantly upregulated (Figures 4–7) in SDS treated ani-
mals. This increase was not associated with enhancement in
the number of leucocytes or neutrophils in CVLs (data not
shown). ELISA results of CVLs were in perfect agreement
with immunohistochemical data (Figure 8).
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Figure 5: Immunohistochemical localization of IL-6 in the cervi-
covaginal tissue after intravaginal application of nisin (15.15mM
in 2mL of 1% polycarbophil gel) (b), SDS (56μMi n2 m Lo f
1% polycarbophil gel) (c) and 2mL 1% polycarbophil gel (a) for
14 consecutive days. To rule out the nonspeciﬁc binding, sections
were incubated in preimmune sera instead of primary antibody and
considered as negative control (d). Semiquantitative comparison by
measuringintegratedopticaldensity(IOD)ofimmunoreactiveIL-6
isshown(e).TheIODineachareawasthenmeasuredforthebrown
color immunoprecipitates. Each value is the mean ± SD of six
observations obtained from three independent samples. The ﬁgure
shown is representative pictures from three independent rabbits
(Mag X 20). (EC = epithelial cells, SE = squamous epithelium, LP
= lamina propria) (∗ = value are statistically signiﬁcant at P<. 05).
3.5. DeterminationofNF-kBP65inCVEcells
Modulation of NF-kB-related signals was determined after
intravaginal application of nisin gel and compared with
placebo gel-administered group. The phosphorylation state
of NF-kB and consequent changes in gene expression
following NF-kB modulation were determined by ELISA
by comparing relative amounts of phosphorylated NF-kB
protein to the total NF-kB protein. Exposure of CVE to
SDS gel triggered a marked activation of NF-kB. However,Sadhana M. Gupta et al. 7
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Figure 6: Immunohistochemical localization of IL-10 in the CVE
after intravaginal application of nisin gel (15.15mM in 2mL of 1%
polycarbophil gel) (b), SDS (56μM in 2mL of 1% polycarbophil
gel) (c) and 2mL of 1% polycarbophil gel for 14 consecutive days.
To rule out the nonspeciﬁc binding, sections were incubated in
preimmune sera instead of primary antibody and considered as
negative control (d). Semiquantitative comparison by measuring
integratedopticaldensity(IOD)ofimmunoreactiveIL-10intreated
and placebo is shown (e). The IOD in each area was then measured
for the brown color immunoprecipitates. Each value is the mean ±
SD of six observations obtained from three independent samples.
Figure shown is representative picture from three independent
experiments. (Mag X 20) (EC = epithelial cells, SE = squamous
epithelium, LP = lamina propria), (∗ = values are statistically
signiﬁcant at P<. 05).
such induction in NF-kB signalling was not observed in
nisin gel treated animals and the placebo gel-treated group
(Figure 10).
3.6. RT-PCRanalysisofrabbitdefensin-1
To examine whether the observed increase in cytokine levels
is associated with changes in vaginal mucosal immunity, we
evaluated the expression of defensin-1 gene in CVE cells.
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Figure 7: Immunohistochemical localization of TNF-α in the cer-
vicovaginal tissue after intravaginal application of nisin (15.15mM
in 2mL of 1% polycarbophil gel) (b), SDS (56μMi n2m Lo f1 %
polycarbophil gel) (c) and 2mL of 1% polycarbophil gel (a) for
14 consecutive days. To rule out the nonspeciﬁc binding, sections
were incubated in preimmune sera instead of primary antibody and
considered as negative control (d). Semiquantitative comparison
by measuring integrated optical density (IOD) of immunoreactive
TNF-α in treated and placebo is shown (e). The IOD in each area
was then measured for the brown color immunoprecipitates. Each
value is the mean ± SD of six observations obtained from three
independent samples. Figure shown is representative picture from
three independent experiments. (Mag X 20) (EC = epithelial cells,
SE = squamous epithelium, LP = lamina propria) (∗ = values are
statistically signiﬁcant at P<0.05).
The results from three independent experiments revealed
that nisin gel treatment did not cause any alterations in the
mRNA expression of defensin-1 compared to placebo gel-
treated group. Whereas in SDS gel treated group expression
of defensin-1 gene was markedly elevated (Figure 11).
4. DISCUSSION
Topical microbicides are being evaluated as promising
strategies for the prevention of STIs/HIV while protecting8 Mediators of Inﬂammation
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Figure 8: Levels of cytokines (IL-4, IL-6, IL-10 and TNF-α) in CVL
after intravaginal application of nisin (15.15mM in 2mL of 1%
polycarbophil gel) SDS (56μM in 2mL of 1% polycarbophil gel)
and 2mL of 1% polycarbophil gel for 14 consecutive days. CVL are
collected on day 15, separated from cell debris by centrifugation
and used for cytokine determination as per the protocol given in
the material and methods section. Each value is the mean ± SD
of six observations from three separate experiments. No signiﬁcant
diﬀerence in cytokine levels was observed between placebo and
nisin gel treated groups. In contrast the levels were signiﬁcantly
increased in SDS gel treated animals (∗ = values are statistically
signiﬁcant at P<0.05).
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Figure 9: RT-PCR analysis of cytokine expression following
intravaginal application of nisin (15.15mM/day/14 days), SDS
(56μM/day/14 days) and 1% placebo gels in rabbits. After sepa-
ration of cells, they were subjected to RNA extraction as per the
protocol given in the material and methods section. The expression
of IL-4, IL-6, IL-10 and TNF-α. genes in nisin treated group was
comparable to the placebo group. In contrast, expression of the
cytokinegeneswasupregulatedinSDStreatedgroup.GAPDHblots
conﬁrmed roughly equivalent loading of RNA samples.
or enhancing the natural mucosal barrier [27, 28]. Nisin,
a naturally occurring AMP, is currently being developed
as an intravaginal microbicide for the prevention of STIs
and unintended pregnancies [8]. To screen nisin gel for
undesirable characteristics if any in a preclinical setting, we
chose the rabbit model, since it has been documented that
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Figure 10: Determination of total and phosphorylated NF-kB
p65 protein levels by ELISA as per the protocol described in
materials and methods. No change was observed in total NF-kB
levels. However, the phosphorylated NF-kB protein levels were
signiﬁcantly elevated in SDS gel administered animals.
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Figure 11: RT-PCR analysis of defensin-1 gene in CVE cells of
rabbit. No change was seen in defensin-1 gene expression between
nisin gel and placebo gel administered groups. However, signiﬁcant
activation of defensin-1 gene expression was observed in SDS gel
administered group compared to placebo and nisin gel treated
animals.
responsiveness of rabbit vagina to microbicides resembles
that of the human vagina [29].
Immunomodulation inﬂammation has been implicated
to play a role in vaginal innate immunity [30]. Inﬂamma-
tory responses limit the beneﬁcial eﬀect of microbicides,
which could be of particular concern if the inﬂammation
persists beyond the time the microbicide was present [29].
Vaginal epithelial cells represent the predominant resident
innate immune cell in the vagina and may modulate the
inﬂammatory response to microbicides [31]. Mammalian
Toll-like receptors (TLRs), including TLR-1 to TLR11, serve
an important role as sensors in host defense mechanism
[32]. On the basis of TLR role in the modulation of innate
immunity and responses to inﬂammatory challenge, we
examined the expression of TLR-3 and 9 as these play a
crucial role in the recognition of inﬂammatory stimuli in
host vaginal immune defense [33, 34].
Under conditions of their intended use as intravagi-
nal/rectal microbicides, individuals would be exposed to
microbicides for shorter or longer periods. Therefore, high
dose of nisin gel (15.15mM in 2mL of 1% polycarbophil)
per day for 14 consecutive days was administered in rabbitsSadhana M. Gupta et al. 9
to ensure whether the estimated risk/beneﬁt proﬁle of the
gel is in favor of its intended use. The immunoﬂuorescent
results demonstrated localization of TLRs-3 and 9 on the
plasma membrane as well as in endosomes present in the
cytoplasm of CVE cells. TLR expression did not change
in the CVE cells of nisin and placebo gel-treated groups.
Theseresultswereinagreementwiththeﬂowcytometrydata
where no change in percent immunoreactive cells expressing
TLRs-3 and 9 was observed. However, the number of cells
expressing both TLRs-3 and 9 were signiﬁcantly elevated in
SDS gel-treated animals. The studies were extended further
to gain an insight into the regulation of TLR expression at
the molecular level. RT-PCR results demonstrated no change
in the expression of TLRs-3 and 9 mRNA transcripts in CVE
cells of nisin gel-treated rabbits compared to the placebo gel-
treated group, suggesting that vaginal application of nisin gel
didnotinduceanyinﬂammationassociatedalterationsatthe
transcriptional and translational level. The CVE cells recog-
nize tissue inﬂammation by means of TLR-3 and 9, likely
through a nonspeciﬁc mechanism. These results tempted us
to speculate that signalling through TLRs may be involved
in mechanisms provoking Th2-based immune responses and
may either prevent or promote vaginal inﬂammation [35].
Earlier studies have suggested that many of the local
inﬂammatory responses initiated in the vaginal mucosa
are mediated by a complex interplay between TLRs and
inﬂammatory agents in the human vagina [32, 36]. In
an elegant study, Fichorova et al. [33] have shown the
presence of TLR 1-6 genes in primary and immortalized
endocervical, ectocervical, and vaginal epithelial cell lines.
They demonstrated mRNA for TLRs-1, 2, 3, and 6 in these
cells. In contrast, no PCR product was detected for TLR-4 in
either of the cells. It has been shown recently that agonists of
TLR-2(zymogen),TLR-3[poly(I:C)],TLR-5(ﬂagellin),and
TLR-9 (CpG ODN) are known to stimulate various immune
cells to secrete several proinfammatory cytokines [23]. These
studies support our present observations that nisin gel did
not upregulate the levels of inﬂammatory cytokines secreted
by CVE cells. In contrast, in SDS gel-treated animals, the
levels of cytokines in the vaginal tissue and vaginal ﬂuid
were upregulated in a TLR-3/9-dependent manner probably
to slow down the tissue inﬂammation.
To further dissect the mechanism, we next investigated
the expression of NF-kB, known for its ability to regulate
cytokine and defensin-1 expression in CVE cells. As shown
in Figure 10, the phospho NF-kB p65 and total NF-kBp 6 5
remainedunchangedinplaceboandnisingel-treatedgroups,
suggesting that vaginal application of nisin gel did not alter
the NF-kB signalling cascade.
We further evaluated the expression of defensin-1 which
is the principal eﬀector molecule of mucosal innate immu-
nity against infection/inﬂammation [37]. Considering the
fact that several defensins are expressed by neutrophils,
epithelial cells, macrophages, NK cells, and T cell subsets
in human [38, 39], the present results indicated that, nisin
gel treatment did not cause any change in the expression of
defensin-1 gene suggesting that the NF-kB signalling cascade
was not aﬀected. The aforementioned studies demonstrated
that nisin gel may either enhance or maintain the normal
immune status to assist in the resolution of inﬂammation,
while SDS gel appears to cause immunosuppressive eﬀect.
Therefore, we hypothesized that TLRs or cytokines
appear to be predictive biomarkers for evaluating the inﬂam-
matory status of vaginal mucosa upon microbicide adminis-
tration. These results are supported by the fact that soluble
TLRs-2 and 4 modulate speciﬁc TLR-mediated responses,
thereby providing new biomarkers of tissue inﬂammation
[40].ThepresentdataledustopostulatethatTLRsappearto
be crucial mediators of vaginal defense and when perturbed
cause inﬂammatory pathways to predominate in CVE cells
leading to mucosal damage. These ﬁndings contribute to
our understanding of mucosal immunity against STIs/HIV
and can aid in enhancing the quality of woman’s repro-
ductive health. Establishing downstream targets for TLR–
microbicide interaction may further unravel the intricacies
of vaginal function.
The present study is the ﬁrst to provide evidence of nisin
gelasasafeintravaginalcompoundforfutureuseinhumans.
Testing additional compounds in the presently planned
clinical trials would allow validation of this approach
and determine whether this safe and inexpensive strategy
provides a surrogate biomarker to predict microbicide safety
and eﬃcacy. However, this study is too small to make a
deﬁnite conclusion. If conﬁrmed in a larger sample, this
strategy could be used to determine which future generation
microbicides should go forward in development, possibly
resulting in major cost savings. However, given the nascent
state of knowledge concerning this important area, it is clear
thatmorestudiesareneededtoprovidevaluableinsightsinto
the biology of TLRs and vaginal innate immunity.
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